Novel Insights in Perioperative Neuroprotection in Neonatal Congenital Heart Disease

Sonia Garcés-Sánchez1,2, Álvaro Solaz-García2, José L López Guillén3

  • 1Anesthesiology and Resuscitation Department, University and Polytechnics Hospital La Fe, Valencia, Spain.

Insights

Congenital heart disease (CHD) can cause neurodevelopmental deficits. This study explores emerging neuroprotective strategies during neonatal cardiac surgery to prevent lifelong neurological injury in infants with CHDs.

Area of Science:

  • Pediatric Cardiology
  • Neonatal Neurology
  • Congenital Anomalies

Background:

  • Congenital heart disease (CHD) encompasses intrauterine cardiac development defects affecting newborn heart morphology and physiology.
  • CHDs are common congenital anomalies with significant neurodevelopmental deficits impacting patients from infancy to adulthood.
  • The perioperative period of neonatal cardiac surgery is a critical time for potential neurological injury in CHD patients.

Purpose of the Study:

  • To describe emerging neuroprotective strategies for neonatal patients with congenital heart disease.
  • To advance understanding of neurodevelopmental trajectories and risk factors in CHDs.
  • To identify interventions mitigating perioperative neurological injury.

Main Methods:

  • Literature review of recent research on neuroprotection in neonatal cardiac surgery.
  • Analysis of factors influencing neurodevelopmental outcomes in CHD.
  • Synthesis of emerging neuroprotective strategies.

Main Results:

  • Recent research has improved understanding of neurodevelopmental trajectories in CHDs.
  • Several factors increase neurodevelopmental risk in these patients.
  • Emerging neuroprotective strategies show promise for mitigating perioperative neurological injury.

Conclusions:

  • Neurodevelopmental deficits are a significant concern for infants with CHDs.
  • The perioperative period of neonatal cardiac surgery poses a risk for neurological injury.
  • Emerging neuroprotective strategies are crucial for improving long-term outcomes in neonatal CHD patients.